Spearhead Capital Advisors’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-8,627
Closed -$225K 193
2022
Q1
$225K Buy
+8,627
New +$245K 0.03% 177

Other funds holding HCAT

Spearhead Capital Advisors's HCAT Position: Q2 2022 in Review

Spearhead Capital Advisors sold out of Health Catalyst (HCAT) in Q2 2022, closing a stake of 8,627 shares — an estimated $225K sold.

Spearhead Capital Advisors first reported a position in HCAT in Q1 2022 and held it in 1 quarter. The position peaked at $225K in Q1 2022. 180 funds tracked by Wall St. Rank hold HCAT as of Q2 2022.

  • Spearhead Capital Advisors reported no remaining Health Catalyst position as of Q2 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 8,627 Health Catalyst shares in Q2 2022, an estimated $225K.
  • Spearhead Capital Advisors first reported a position in Health Catalyst in Q1 2022 and held it in 1 quarter.
  • Spearhead Capital Advisors's Health Catalyst position peaked at $225K in Q1 2022.
  • 180 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2022.

Based on Spearhead Capital Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.